• 主题
高级搜索  >
历史搜索 清空历史
首页> 外文期刊>Artificial Organs >Clearance of drugs for multiple myeloma therapy during in vitro high-cutoff hemodialysis
【24h】

Clearance of drugs for multiple myeloma therapy during in vitro high-cutoff hemodialysis

机译：体外高临界血液透析期间清除用于多发性骨髓瘤治疗的药物

获取原文
获取原文并翻译 | 示例
           
页面导航
  • 摘要
  • 著录项
  • 相似文献
  • 相关主题

摘要

Current chemotherapy for multiple myeloma is based on bortezomib (BOR), dexamethasone (DEX), and thalidomide (THA). The purpose of the present study was to examine their clearance during high-cutoff (HCO) hemodialysis and to accordingly apply the results to the dialytic removal of protein-bound substances in general. During in vitro hemodialysis with human blood (blood, dialysate, and ultrafiltration flow rates 250, 500 and 5mL/min, respectively) comparing a highly permeable HCO dialyzer (Theralite, 2.1m2) to a high-flux dialyzer (PFX; 2.1m2), ultrafiltered volume was replaced by saline containing 30g/L urea. After recirculation for equilibration, BOR was injected, and arterial and venous samples were drawn after 10, 11, and 12min to measure the plasma clearance (K) of both urea and BOR. The same procedure was performed with THA and DEX. By mathematical simulation, the influence of varying plasma albumin concentrations (CHSA) on the protein-bound drug fraction (PBF) and K was assessed. Plasma K values of HCO and PFX for THA, BOR, and DEX were about 40% (80±7 vs. 65±6mL/min; P0.05), 70% (40±8 vs. 33±4mL/min; P0.05), and 65% (47±11 vs. 38±7mL/min; P0.05), respectively-lower (P0.0001) compared with urea (125±7 vs. 122±5mL/min). K was highest (P0.0001) for THA. K was negatively correlated with CHSA (THA, r2=0.58, P0.001; BOR, r2=0.24, P0.05; DEX, r2=0.22, P0.05). CHSA continually decreased (P0.05) over time only with HCO, resulting in lower calculated PBF. Compared with BOR and DEX (minimum 72 and 56%, respectively), the PBF of THA (37%) was significantly lower (P0.001). A mathematical simulation based on the K values of urea and the drugs reliably estimated PBF (r2=0.886, P0.001). Drugs for multiple myeloma therapy are significantly removed with both HCO and PFX, with important implications for the dosing and timing of administration, particularly in patients with cast nephropathy receiving extended dialysis. If the Kurea of a dialyzer and the PBF of any given drug are known, Kdrug can be reliably estimated by mathematical simulation.
机译：当前的多发性骨髓瘤化疗基于硼替佐米（BOR），地塞米松（DEX）和沙利度胺（THA）。本研究的目的是检查其在高截止（HCO）血液透析过程中的清除率，并将其结果相应地应用于一般性去除蛋白结合物的透析过程。在用人血进行体外血液透析时（血液，透析液和超滤流速分别为250、500和5mL / min），将高渗透性HCO透析器（Theralite，2.1m2）与高通量透析器（PFX; 2.1m2）进行比较，用30g / L尿素代替生理盐水。再循环以达到平衡后，注入BOR，并在10、11和12分钟后抽取动脉和静脉样本以测量尿素和BOR的血浆清除率（K）。使用THA和DEX进行相同的过程。通过数学模拟，评估了血浆白蛋白浓度（CHSA）的变化对结合蛋白的药物部分（PBF）和K的影响。 THA，BOR和DEX的HCO和PFX的血浆K值约为40％（80±7对65±6mL / min; P <0.05），70％（40±8对33±4mL / min; P <0.05）和65％（47±11 vs. 38±7mL / min; P <0.05）分别低于尿素（125±7 vs. 122±5mL / min）（P <0.0001）。 THA的K最高（P <0.0001）。 K与CHSA呈负相关（THA，r2 = 0.58，P <0.001; BOR，r2 = 0.24，P <0.05; DEX，r2 = 0.22，P <0.05）。仅使用HCO，CHSA随时间推移持续下降（P <0.05），从而导致计算出的PBF降低。与BOR和DEX相比（分别为最低72％和56％），THA的PBF（37％）显着更低（P <0.001）。基于尿素和药物的K值的数学模拟可靠地估算了PBF（r2 = 0.886，P <0.001）。 HCO和PFX均明显清除了用于多发性骨髓瘤治疗的药物，这对给药的剂量和给药时间具有重要意义，尤其是在接受长期透析的铸型肾病患者中。如果知道透析器的Kurea和任何给定药物的PBF，则可以通过数学模拟可靠地估计Kdrug。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱：kefu@zhangqiaokeyan.com

京公网安备：11010802029741号 ICP备案号：京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有

  • 客服微信

  • 服务号